IBD Needs Innovation

Inflammatory bowel disease (IBD) affects over 10 million people worldwide.1 In spite of significant scientific progress in the understanding of chronic inflammatory diseases, many patients continue to face challenges controlling their disease.2

Gilead and Galapagos have formed a unique partnership, combining strengths and expertise, to help address these challenges. We’re doing more and moving faster, together.

IBD Needs Innovation

Enter Site